SG10201407538WA - Intravenous formulations of neurokinin-1 antagonists - Google Patents

Intravenous formulations of neurokinin-1 antagonists

Info

Publication number
SG10201407538WA
SG10201407538WA SG10201407538WA SG10201407538WA SG10201407538WA SG 10201407538W A SG10201407538W A SG 10201407538WA SG 10201407538W A SG10201407538W A SG 10201407538WA SG 10201407538W A SG10201407538W A SG 10201407538WA SG 10201407538W A SG10201407538W A SG 10201407538WA
Authority
SG
Singapore
Prior art keywords
neurokinin
antagonists
intravenous formulations
pharmaceutical compositions
methods
Prior art date
Application number
SG10201407538WA
Inventor
Jiansheng Wan
Pranav Gupta
David Monteith
Soumendu Bhattacharya
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of SG10201407538WA publication Critical patent/SG10201407538WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pharmaceutical compositions for intravenous administration comprising the compound of Formula I, or pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and/or emesis with the pharmaceutical compositions are also described herein. FIGURE 4. 72
SG10201407538WA 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists SG10201407538WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23412909P 2009-08-14 2009-08-14

Publications (1)

Publication Number Publication Date
SG10201407538WA true SG10201407538WA (en) 2015-01-29

Family

ID=43586486

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012010146A SG178403A1 (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists
SG10201407538WA SG10201407538WA (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012010146A SG178403A1 (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists

Country Status (15)

Country Link
US (2) US9101615B2 (en)
EP (2) EP2464230B1 (en)
JP (2) JP5860399B2 (en)
KR (1) KR101834577B1 (en)
CN (2) CN102573475B (en)
AU (1) AU2010282483B2 (en)
BR (1) BR112012003263A2 (en)
CA (1) CA2770403C (en)
ES (1) ES2609640T3 (en)
IL (1) IL217942A0 (en)
MX (1) MX336071B (en)
RU (2) RU2642234C2 (en)
SG (2) SG178403A1 (en)
TW (2) TWI498329B (en)
WO (1) WO2011019911A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201500028RA (en) 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
JP5352446B2 (en) 2006-04-05 2013-11-27 オプコ ヘルス， インコーポレイテッド Hydrochloric acid of 8-[{1- (3,5-bis- (trifluoromethyl) phenyl) -ethoxy} -methyl] -8-phenyl-1,7-diaza-spiro [4.5] decan-2-one Salt and its preparation process
AR066191A1 (en) 2007-03-22 2009-08-05 Schering Corp PROCESS AND INTERMEDIARIES FOR THE SYNTHESIS OF COMPOUNDS 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) PHENYL) - ETOXI) - METAL] - 8 PHENYL - 1,7- DIAZA - ESPIRO (4, 5) DECAN - 2 ONA
EP2346823B1 (en) 2008-09-05 2015-08-19 OPKO Health, Inc. Intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
RU2642234C2 (en) 2009-08-14 2018-01-24 ОПКО Хельс, Инк. Antagonists neurokinin-1 compositions for intravenous introduction
AR097683A1 (en) * 2013-09-26 2016-04-06 Lilly Co Eli COMPOUNDS AND USE FOR THE PREPARATION OF TAU IMAGE TRAINING AGENTS AND FORMULATIONS FOR TAU IMAGE FORMATION
KR102424837B1 (en) 2014-09-19 2022-07-25 헤론 테라퓨틱스 인코포레이티드 Emulsion formulations of aprepitant
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US9974742B2 (en) * 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
EP3411013A1 (en) * 2016-02-01 2018-12-12 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
US20190175702A1 (en) * 2016-08-03 2019-06-13 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
CN109963583B (en) * 2016-11-21 2023-06-09 珠海贝海生物技术有限公司 Latiflutamine preparation
CA3059418A1 (en) 2017-04-10 2018-10-18 Chase Therapeutics Corporation Nk1-antagonist combination and method for treating synucleinopathies
US11260028B2 (en) 2017-06-26 2022-03-01 Fordoz Pharma Corp. Nanosome formulations of aprepitant and methods and applications thereof
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
CN109200018A (en) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 Containing how the smooth microemulsion formulation of appropriate pyrrole
CN108703950B (en) * 2018-08-27 2021-04-20 辅必成（上海）医药科技有限公司 Emulsion injection of Lapiaptan
CN109453115A (en) * 2018-12-25 2019-03-12 广州白云山汉方现代药业有限公司 A kind of smooth intravenous injection emulsion of roller and its preparation method and application
CN109394693A (en) * 2018-12-25 2019-03-01 广州白云山汉方现代药业有限公司 A kind of smooth emulsion of roller and its preparation method and application
AU2020308397A1 (en) 2019-06-28 2022-02-17 Jiangsu Hengrui Medicine Co., Ltd. Neurokinin-1 antagonist
US20230190740A1 (en) 2020-04-03 2023-06-22 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
CN115697332A (en) 2020-06-02 2023-02-03 尼尔医疗有限公司 Neurokinin (NK) -1 receptor antagonists for the treatment of pulmonary fibrotic conditions promoted by mechanical injury of the lung
EP4268818A4 (en) 2020-12-25 2024-06-19 Shanghai Shengdi Pharmaceutical Co., Ltd Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist
WO2023134723A1 (en) * 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 Crystal form of neurokinin-1 antagonist prodrug compound
TW202332428A (en) * 2022-01-12 2023-08-16 大陸商江蘇恒瑞醫藥股份有限公司 Pharmaceutical composition containing prodrug compoound of neurokinin-1 antagonist

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338372A3 (en) * 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
EP0595796B1 (en) * 1989-07-07 2003-01-15 Endorecherche Inc. Method of treatment of androgen-related diseases
US5610140A (en) * 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
JPH08502510A (en) 1992-10-28 1996-03-19 メルク シヤープ エンド ドーム リミテツド Arylmethyloxymethylpiperidine as a tachykinin antagonist
JPH08504435A (en) 1992-12-14 1996-05-14 メルク シヤープ エンド ドーム リミテツド 4-Aminomethyl / thiomethyl / sulfonylmethyl-4-phenylpiperidine as tachykinin receptor antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
EP0739336B1 (en) 1994-01-13 1998-08-26 MERCK SHARP & DOHME LTD. Gem-disubstituted azacyclic tachykinin antagonists
KR100405116B1 (en) 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. Pharmaceutical compositions for piperidino alkanol compounds
SE9503143D0 (en) * 1995-09-12 1995-09-12 Astra Ab New preparation
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
DE69728883T2 (en) 1996-07-17 2005-04-07 Merck & Co., Inc. CHANGING THE CIRCADIC RHYTHM WITH NONPEPTIDIC NEUROKININ-1 RECEPTOR ANTAGONISTS
JP2001523245A (en) 1997-04-24 2001-11-20 メルク シヤープ エンド ドーム リミテツド Use of NK-1 receptor antagonists and SSRIs to treat obesity
JP3571511B2 (en) * 1997-11-11 2004-09-29 トーアエイヨー株式会社 Transdermal formulation
US6380242B1 (en) * 1998-12-23 2002-04-30 Nps Allelix Corp. N-alkylamino-indoles for the treatment of migraine
BR0010794A (en) * 1999-05-24 2002-06-04 Sonus Pharma Inc Emulsion-vehicle for drugs with poor solubility
AU2097601A (en) 1999-12-17 2001-06-25 Schering Corporation Selective neurokinin antagonists
US6436928B1 (en) 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
TWI270545B (en) * 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US7183272B2 (en) * 2001-02-12 2007-02-27 Teva Pharmaceutical Industries Ltd. Crystal forms of oxcarbazepine and processes for their preparation
ATE374183T1 (en) 2001-11-13 2007-10-15 Schering Corp NK1 ANTAGONISTS
PE20030762A1 (en) * 2001-12-18 2003-09-05 Schering Corp HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
WO2004082676A1 (en) 2003-03-13 2004-09-30 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
CN1678317B (en) * 2002-07-03 2010-10-27 先灵公司 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(NK-1) antagonists for the treatment of emesis, depression, anxiety and cough
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
GB0321256D0 (en) * 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
WO2005033107A1 (en) 2003-10-03 2005-04-14 Pfizer Limited Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
PL380482A1 (en) * 2003-12-22 2007-02-05 Schering Corporation Pharmaceutical compositions
CA2570197C (en) * 2004-07-01 2013-09-10 Schering Corporation Nk1 antagonists
US7871632B2 (en) * 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
JP2008521834A (en) * 2004-11-30 2008-06-26 ミリアド ジェネティクス， インコーポレイテッド Therapeutic formulation
CN100367951C (en) 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 Butyl benzene phthalein vein emulsion and its application
PE20071019A1 (en) * 2006-03-06 2007-10-29 Wyeth Corp LIQUID AND SEMI-SOLID PHARMACEUTICAL FORMULATIONS INCLUDING A STROGEN RECEPTOR MODULATOR
SG10201500028RA (en) 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
JP5352446B2 (en) 2006-04-05 2013-11-27 オプコ ヘルス， インコーポレイテッド Hydrochloric acid of 8-[{1- (3,5-bis- (trifluoromethyl) phenyl) -ethoxy} -methyl] -8-phenyl-1,7-diaza-spiro [4.5] decan-2-one Salt and its preparation process
CN101110758A (en) 2006-07-21 2008-01-23 华为技术有限公司 Method and system for establishing emergency conversation and proxy function of controlling call conversation
WO2008021049A2 (en) * 2006-08-07 2008-02-21 Stiefel Laboratories, Inc. Crystalline antifungal compounds
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
AR066191A1 (en) * 2007-03-22 2009-08-05 Schering Corp PROCESS AND INTERMEDIARIES FOR THE SYNTHESIS OF COMPOUNDS 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) PHENYL) - ETOXI) - METAL] - 8 PHENYL - 1,7- DIAZA - ESPIRO (4, 5) DECAN - 2 ONA
AR065802A1 (en) 2007-03-22 2009-07-01 Schering Corp FORMULATIONS OF TABLETS CONTAINING SALTS OF 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) FENIL) -ETOXI) - METHYL) -8- PHENYL -1, 7- DIAZA- SPIRO [4,5] DECAN - 2- ONA AND TABLETS PREPARED FROM THESE
EP2346823B1 (en) 2008-09-05 2015-08-19 OPKO Health, Inc. Intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
RU2642234C2 (en) 2009-08-14 2018-01-24 ОПКО Хельс, Инк. Antagonists neurokinin-1 compositions for intravenous introduction

Also Published As

Publication number Publication date
CA2770403C (en) 2020-09-01
EP2464230A4 (en) 2013-01-02
CN102573475B (en) 2016-01-20
BR112012003263A2 (en) 2015-09-22
AU2010282483B2 (en) 2014-09-04
TWI498329B (en) 2015-09-01
EP2464230B1 (en) 2016-10-05
IL217942A0 (en) 2012-03-29
US20160024092A1 (en) 2016-01-28
CN105503870A (en) 2016-04-20
CA2770403A1 (en) 2011-02-17
MX336071B (en) 2016-01-06
EP3143996A1 (en) 2017-03-22
KR20120060215A (en) 2012-06-11
US9101615B2 (en) 2015-08-11
MX2012001872A (en) 2012-04-11
KR101834577B1 (en) 2018-03-05
TW201604195A (en) 2016-02-01
US20110038925A1 (en) 2011-02-17
JP2016041734A (en) 2016-03-31
CN102573475A (en) 2012-07-11
SG178403A1 (en) 2012-03-29
JP5860399B2 (en) 2016-02-16
ES2609640T3 (en) 2017-04-21
WO2011019911A1 (en) 2011-02-17
JP6308991B2 (en) 2018-04-11
RU2017145628A (en) 2019-02-19
RU2642234C2 (en) 2018-01-24
RU2012109405A (en) 2013-09-20
TW201111382A (en) 2011-04-01
EP2464230A1 (en) 2012-06-20
JP2013501806A (en) 2013-01-17
AU2010282483A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
SG10201407538WA (en) Intravenous formulations of neurokinin-1 antagonists
MX2021008356A (en) Jak2 and alk2 inhibitors and methods for their use.
MX2020010151A (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions.
MX2013003019A (en) Azabenzothiazole compounds, compositions and methods of use.
MX2016001400A (en) 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions.
IN2012DN03337A (en)
UA109868C2 (en) N -alkyltriazole compounds asr
MX2011013771A (en) 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17.
HK1149258A1 (en) Compounds
MX2009009238A (en) Novel phosphodi esterase inhibitors.
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
MX2010002584A (en) Piperidine derivatives as agonists of muscarinic receptors.
MX2013000474A (en) Novel arylamide derivatives having antiandrogenic properties.
IN2012DN01232A (en)
IN2012DN04868A (en)
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MX2010009395A (en) Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177.
MX2010009756A (en) Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof.
TN2014000060A1 (en) Benzothiazolone compound
WO2015002755A3 (en) Compounds for the treatment of malaria
MY156955A (en) Antifungal agents
IN2012DN01234A (en)
MX2009001572A (en) Arylpiperazine derivatives and uses thereof.
PL2065035T3 (en) Pharmaceutical formulations containing irbesartan